New InhibitorSelect Library III Collection From EMD Chemicals Offers 84 Well-Characterized Kinase Inhibitors

GIBBSTOWN, N.J.–EMD Chemicals Inc., a manufacturer of high-quality inhibitors, biochemicals, antibodies, proteins and kits, recently introduced InhibitorSelect™ 96-well Protein Kinase Inhibitor Library III as part of its continuing endeavor to offer convenient, cost-effective products to life science researchers. This unique collection of 84 structurally diverse and potent inhibitors, which mainly target the CMGC, CaMK, AGC and STE families of kinases, serves as a complement to the InhibitorSelect™ 96-well Protein Kinase Library II.

InhibitorSelect™ libraries contain well-characterized, pharmacologically active and structurally diverse InSolution™ inhibitors in 96- or 384-well formats, and speed up results and lower costs by reducing screening requirements. These scientifically selected and validated inhibitors ensure cell permeability, reversibility and potency. Stringent stability and HPLC purity testing on every batch of plates ensures reliable results, the first time and every time.

“This new inhibitor library is a continuation of our leadership in kinase research and our commitment to innovate the Calbiochem® brand inhibitor product offering,” said Christina Shassere, General Manager, EMD Chemicals Inc., Global Bioscience.

InhibitorSelect™ products are suitable for a wide variety of applications and are provided with comprehensive documentation, such as molecular structure, IC50 values, literature citations, and CAS number, where available. Additional libraries are being introduced on a regular basis. For more information about the current inhibitor library portfolio or to download comprehensive documentation on the inhibitors included in each library, visit www.emdbiosciences.com/InhibitorSelect.

About EMD Chemicals Inc.

EMD Chemicals Inc. represents the North American chemical sector of Merck KGaA, Darmstadt, Germany. It is an international organization with nearly 1,000 employees and revenues of more than $US 300 million in 2008, providing specialty chemicals for pharmaceutical, biotech, cosmetic, automotive, plastics and other industrial applications. With headquarters in Gibbstown, N.J., EMD Chemicals Inc. is also engaged in the development, manufacture and distribution of a broad array of reagents used for life science research. Its sister company, EMD Crop BioScience Inc. located in Milwaukee, Wis., specializes in plant growth enhancement products for agricultural applications, including Optimize®. EMD Chemicals Inc. is known in the market for its product brands Iriodin®, Xirallic®, Rona®, Calbiochem®, Novabiochem® and Novagen®, among others.

About Merck KGaA

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to https://www.subscribe.merck.de to register online, change your selection or discontinue this service.

Merck is a global pharmaceutical and chemical company with total revenues of € 7.6 billion in 2008, a history that began in 1668, and a future shaped approximately 33,000 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.